ATTO-004

ATTO-004 is a multi-specific drug candidate in preclinical development for the treatment of immune-mediated diseases, specifically targeting inflammatory bowel disease (IBD). It is being developed by Attovia using their proprietary ATTOBODY platform, which enables the creation of biotherapeutics with biparatopic binding modes for ultra-high affinity and best-in-class potency. The modular nature of the technology allows for engineering multi-specific biologics with tunable half-life, potentially enabling infrequent dosing schedules. The precise molecular targets and mechanisms of action for ATTO-004 have not been publicly disclosed as of April 2025[1][2][5].